Alternative sunitinib dosing schedule for the treatment of kidney cancer improves adverse events

Recently, the results of several studies have demonstrated that a 2 weeks on treatment, 1 week off treatment (2/1) dosing schedule for sunitinib improves adverse events, without reducing efficacy, in patients with metastatic renal cell carcinoma (RCC).

Read a review article here and an article presenting real world evidence with a 2/1 dosing schedule for sunitinib here

Share this Post!

Related post